Scholarlink

Background <p>Cutaneous T-cell lymphoma (CTCL) is a rare malignancy with limited data available from the Middle East. This study evaluated the clinical characteristics, treatment patterns, and outcomes of CTCL patients treated in Kuwait.</p> Methods <p>This was a retrospective review of all adult patients diagnosed between February 2021 and March 2024. Data included demographics, staging, treatment modalities, and outcomes. Kaplan–Meier analysis was used to evaluate progression-free survival (PFS) and overall survival (OS).</p> Results <p>The study included 86 patients. The mean age at diagnosis was 44&#xa0;years (range: 16–80), and 84% of patients presented with early-stage disease (IA–IIA). NB-UVB phototherapy was the most common treatment for early-stage disease, while brentuximab vedotin was frequently used for advanced diseases. Median OS was 30&#xa0;months in patients with advanced disease and not reached in those with early-stage disease (p = 0.003). Median PFS was 22&#xa0;months overall, and significantly longer in early-stage than advanced disease (50 vs. 15&#xa0;months, p = 0.009). Advanced stage, blood involvement, and elevated LDH were significant predictors of worse PFS.</p> Conclusion <p>This study provides the first real-world analysis of CTCL outcomes in Kuwait. The findings underscore the importance of early detection and the role of novel therapies in disease management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cutaneous T-cell lymphoma in Kuwait: a retrospective analysis of treatment modalities and prognostic factors

  • 期刊论文

  • 发表日期：

    2026年1月6日

查看全文
  • Rasha Abdel Tawab Hamed,
  • Ahmed Alsarraf,
  • Jihan Rajy,
  • Hasan Ashkanani,
  • Rawan Almutairi,
  • Abdulaziz Hamadah,
  • Atlal AlLafi,
  • K. Pinto,
  • Dina Elkady,
  • Yaser Al Yacoub,
  • Arti Nanda,
  • Salem Alshemmari

摘要

Background

Cutaneous T-cell lymphoma (CTCL) is a rare malignancy with limited data available from the Middle East. This study evaluated the clinical characteristics, treatment patterns, and outcomes of CTCL patients treated in Kuwait.

Methods

This was a retrospective review of all adult patients diagnosed between February 2021 and March 2024. Data included demographics, staging, treatment modalities, and outcomes. Kaplan–Meier analysis was used to evaluate progression-free survival (PFS) and overall survival (OS).

Results

The study included 86 patients. The mean age at diagnosis was 44 years (range: 16–80), and 84% of patients presented with early-stage disease (IA–IIA). NB-UVB phototherapy was the most common treatment for early-stage disease, while brentuximab vedotin was frequently used for advanced diseases. Median OS was 30 months in patients with advanced disease and not reached in those with early-stage disease (p = 0.003). Median PFS was 22 months overall, and significantly longer in early-stage than advanced disease (50 vs. 15 months, p = 0.009). Advanced stage, blood involvement, and elevated LDH were significant predictors of worse PFS.

Conclusion

This study provides the first real-world analysis of CTCL outcomes in Kuwait. The findings underscore the importance of early detection and the role of novel therapies in disease management.